[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index up 0.5% and the Sta",
    "url": "https://finnhub.io/api/news?id=1df8cfce120a059ed30c9706812801d11c0ece6de3dcdeefa78bf25f30c4d331",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770842645,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 139049512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index up 0.5% and the Sta",
      "url": "https://finnhub.io/api/news?id=1df8cfce120a059ed30c9706812801d11c0ece6de3dcdeefa78bf25f30c4d331"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=dd2722e26562bfc6a8689e5f561070f6bdea833069b61e7e7fbea5b01756ecf7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770827580,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 139059409,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=dd2722e26562bfc6a8689e5f561070f6bdea833069b61e7e7fbea5b01756ecf7"
    }
  },
  {
    "ts": null,
    "headline": "EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus",
    "summary": "Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.",
    "url": "https://finnhub.io/api/news?id=8caa5fb3ee878663bf516de2ef81016a30fc5f8901bb34d728fbf7d61dd09753",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770821760,
      "headline": "EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus",
      "id": 139045385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.",
      "url": "https://finnhub.io/api/news?id=8caa5fb3ee878663bf516de2ef81016a30fc5f8901bb34d728fbf7d61dd09753"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case",
    "summary": "Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case",
    "url": "https://finnhub.io/api/news?id=48cb5754c2dda00fd71e39120b3e39b9f6d8a7efb0d2c45c8061f62754bf75d4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770818134,
      "headline": "Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case",
      "id": 139047393,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=48cb5754c2dda00fd71e39120b3e39b9f6d8a7efb0d2c45c8061f62754bf75d4"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
    "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
    "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815340,
      "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
      "id": 139045076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
      "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finnhub.io/api/news?id=c9bdfe3016d669de711536a7380515347459a5ca78c0ae55dc0c7e5529255a11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770810300,
      "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
      "id": 139041046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
      "url": "https://finnhub.io/api/news?id=c9bdfe3016d669de711536a7380515347459a5ca78c0ae55dc0c7e5529255a11"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment",
    "summary": "RAHWAY, N.J., February 11, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peri",
    "url": "https://finnhub.io/api/news?id=4eac94ee9978671dd47d68ef6276ba57d4299e506fefee9b5f52ab2efe70ee0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770810300,
      "headline": "KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment",
      "id": 139041045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 11, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peri",
      "url": "https://finnhub.io/api/news?id=4eac94ee9978671dd47d68ef6276ba57d4299e506fefee9b5f52ab2efe70ee0d"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients",
    "summary": "FDA approves Merck&#39;s Keytruda combo for previously treated ovarian cancer after trial shows longer survival and lower risk of disease progression.",
    "url": "https://finnhub.io/api/news?id=866a35e545fbf50601dce6ef244e1c1b76882df658b5c65789b19f2329f0ffcc",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809213,
      "headline": "Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients",
      "id": 139055339,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/South-San-Francisco--Ca--Usa---May-1--20.jpeg?width=2048&height=1536",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "FDA approves Merck&#39;s Keytruda combo for previously treated ovarian cancer after trial shows longer survival and lower risk of disease progression.",
      "url": "https://finnhub.io/api/news?id=866a35e545fbf50601dce6ef244e1c1b76882df658b5c65789b19f2329f0ffcc"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
    "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
    "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770804000,
      "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
      "id": 139044801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
      "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Approves Merck's Keytruda And Keytruda Qlex Plus Paclitaxel, With Or Without Bevacizumab, For PD-L1+ Platinum-resistant Ovarian Carcinoma",
    "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and",
    "url": "https://finnhub.io/api/news?id=76be3033bb82b857f7f70a47758d3475fe2edaf2c5aa2eebd78ae8e0d690d253",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770796269,
      "headline": "The FDA Approves Merck's Keytruda And Keytruda Qlex Plus Paclitaxel, With Or Without Bevacizumab, For PD-L1+ Platinum-resistant Ovarian Carcinoma",
      "id": 139043490,
      "image": "",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and",
      "url": "https://finnhub.io/api/news?id=76be3033bb82b857f7f70a47758d3475fe2edaf2c5aa2eebd78ae8e0d690d253"
    }
  }
]